Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

Table 4 Clinical trials about Endostar combined with ICIs in NSCLC

	Nature	Inclusion criteria	Patients	Endostar	ICIs	Result	Reference
Lv et.al	clinical	advanced NSCLC with EGFR(-) or ALK(-) and ineffective previous treatment	34	210 mg, continuous intravenous infusion for 168h every 4 weeks	nivolumab (3mg/kg, intravenous drip, day1) every 2 weeks	ORR 41.2%(95%CI:23.7-58.6%) DCR 64.7%(95%CI:47.8–81.6%) CBR 44.1%(95%CI:26.5–61.7%) DOR 6.9m(95%CI:4.4–9.4m) mPFS 6.8m(95%CI: 1.1–12.1) mOS 17.1m (95%CI: 6.6–27.6) grade 1-2 TRAEs 41.1% grade 3-5 TRAEs 11.8%	[19]
Wu et.al	clinical	advanced NSCLC	21	usage not mentioned	Camrelizumab	ORR 71%, DCR 100% thrombocyto-penia 24%,>3 grade 10% nausea and vomiting 24%,>3grade 5% liver damage 19% RCCEP related with camrelizumab>3 grade 0%	[17]
Wu et.al	clinical	advanced stage (IIIB and IV) NSCLC	27	210 mg, continuous intravenous infusion from day 1-3 every 3 weeks	Camrelizumab 200 mg every 3 weeks	ORR 48%, DCR 85%,CR 3.7% mPFS 8.9m anemia67%,>3 grade 11% nausea and vomiting 41%, >3 grade 4% immune-related hepatitis 3.7% RCCEP related with camrelizumab 41%	[18]

ICIs, immune checkpoint inhibitors, NSCLC, non-small cell lung cancer, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, ORR objective response rate, DCR, disease control rate, CBR clinical benefit response rate, DOR duration of response, mPFS median pro-gression-free survival, mOS median overall survival, TRAEs treatment-related adverse events, RCCEP reactive cutaneous capillary endothelial proliferation

ISSN: 1471-2407